Biotech | January 14, 2022
Evonik to build production plant for rhamnolipids in Slovakia
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
The stability is led by healthy demand in the domestic and emerging markets
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Subscribe To Our Newsletter & Stay Updated
